SOPHiA GENETICS SA Shareholders Approve 2024 Financials

Ticker: SOPH · Form: 6-K · Filed: 2025-06-18T00:00:00.000Z

Sentiment: neutral

Topics: agm, financials, reporting

Related Tickers: SOPH

TL;DR

SOPH shareholders rubber-stamped the 2024 financials at the AGM.

AI Summary

On June 18, 2025, SOPHiA GENETICS SA held its annual general meeting where shareholders approved the 2024 Management Report, Annual Financial Statements, and Consolidated Financial Statements. The company is a foreign private issuer filing under the 1934 Act.

Why It Matters

Shareholder approval of financial statements is a routine but necessary step for public companies, indicating transparency and compliance with reporting standards.

Risk Assessment

Risk Level: low — This filing is a routine report of annual general meeting results and financial statement approval, with no new material information or significant changes.

Key Players & Entities

FAQ

What was the purpose of the June 18, 2025 filing?

The purpose was to report the final results of the agenda items voted on at SOPHiA GENETICS SA's annual general meeting held on June 18, 2025.

Which financial statements were approved by shareholders?

Shareholders approved the 2024 Management Report, the Annual Financial Statements, and the Consolidated Financial Statements for the financial year 2024.

Is SOPHiA GENETICS SA filing as a domestic or foreign issuer?

SOPHiA GENETICS SA is filing as a foreign private issuer.

Under which SEC Act is this report filed?

This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What is the principal executive office address of SOPHiA GENETICS SA?

The principal executive office is located at La Pièce 12 CH-1180 Rolle, Switzerland.

From the Filing

0001840706-25-000021.txt : 20250618 0001840706-25-000021.hdr.sgml : 20250618 20250618111441 ACCESSION NUMBER: 0001840706-25-000021 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20250618 FILED AS OF DATE: 20250618 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOPHiA GENETICS SA CENTRAL INDEX KEY: 0001840706 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] ORGANIZATION NAME: 06 Technology EIN: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40627 FILM NUMBER: 251055544 BUSINESS ADDRESS: STREET 1: LA PIECE, CH-1180 CITY: ROLLE STATE: V8 ZIP: 00000 BUSINESS PHONE: 41 21 694 10 60 MAIL ADDRESS: STREET 1: LA PIECE, CH-1180 CITY: ROLLE STATE: V8 ZIP: 00000 6-K 1 agmresults2025sophiageneti.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025. ____________________________________ Commission File Number: 001-40627 SOPHiA GENETICS SA (Exact name of registrant as specified in its charter) La Pièce 12 CH-1180 Rolle Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F On June 18, 2025, SOPHiA GENETICS SA (the “Company”) held its annual general meeting. The final results of each of the agenda items submitted to a vote of the shareholders are set forth below: Item 1: 2024 Management Report, Annual Financial Statements and Consolidated Financial Statements, Auditors’ Reports. The shareholders approved the 2024 Management Report, the Annual Financial Statements and the Consolidated Financial Statements for the financial year 2024 and acknowledged the Auditors’ Reports. The shareholders approved the proposal of the Board of Directors on this item with 38,554,350 votes (99.82% of all ordinary shares represented) in favor, 1,215 votes (0.00%) against and 67,204 (0.17%) abstentions. Item 2: Consultative vote on the 2024 ESG Impact Summary (Sustainability Report). The shareholders approved the proposal of the Board of Directors on this item with 38,535,309 (consultative) votes (99.77% of all ordinary shares represented) in favor, 2,772 votes (0.01%) against and 84,688 (0.22%) abstentions. Item 3: Discharge of the members of the Board of Directors and the Executive Committee. The shareholders approved the discharge of the members of the Board of Directors and the Executive Committee from liability for the financial year 2024. The shareholders approved the proposal of the Board of Directors on this item with 38,399,469 votes (99.42% of all ordinary shares represented) in favor, 87,226 votes (0.23%) against and 136,074 (0.35%) abstentions. Item 4: Appropriation of 2024 Financial Results. The shareholders approved that the net loss of the Company for the financial year 2024 in the amount of CHF 39,621,175 be carried forward, resulting in a total loss of CHF 350,959,680 to be carried forward. The shareholders approved this item with 38,490,274 votes (99.66% of all ordinary shares represented) in favor, 3,172 votes (0.01%) against and 129,323 (0.33%) abstentions. Item 5: Re-election of the Chair&#59; re-election of the Members of the Board of Directors. The shareholders approved the re-election of the following members of the Board of Directors, including the Chair, for a term of office until the completion of the 2026 Annual General Meeting. a. The shareholders approved the re-election of Troy Cox with 37,894,054 votes (98.11% of all ordinary shares represented) in favor, 583,330 votes (1.51%) against and 145,385 (0.38%) abstentions. b. The shareholders approved the re-election of

View on Read The Filing